Latest Amides Stories
WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
Dr. Milton Packer and Dr. McMurray will be presenting these results for the first time in the United States at the HFSA Annual Meeting LAS VEGAS, Sept.
--Phase 2a Trial is First to Use Crowdsourcing for Protocol Design and Telemonitoring for Patient Data Collection-- NEW YORK, Sept.
DALLAS, September 7, 2014 /PRNewswire/ -- MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its
Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone.
Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market SAN ANTONIO, Sept.
The Firm is evaluating Xarelto lawsuits on behalf of patients who suffered uncontrollable internal bleeding, stroke, deep vein thrombosis, pulmonary embolism, or death, allegedly due to their
Patients at higher risk of kidney problems due to existing diabetes were also evaluated for the effects of warfarin on kidney function RIDGEFIELD, Conn., Sept.
Hot Line session presentations to feature renal function data from pivotal RE-LY® trial and global GLORIA(TM)-AF registry updates RIDGEFIELD, Conn., Aug.
- A poem in which the author retracts something said in an earlier poem.